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AbstrACt
Objectives This study was performed to analyse 
anaesthesia-related complications and side effects in 
patients undergoing transcatheter aortic valve implantation 
(TAVI) under general anaesthesia.
Design Retrospective study.
setting The study was performed as a single-centre study 
in a hospital of tertiary care in Germany.
Participants All 853 patients, who underwent TAVI at 
the Universitätsklinikum Regensburg between January 
2009 and July 2015, were included. 52.5% were female 
patients.
Primary and secondary outcome measures We 
gathered information, such as recent illness, vital 
parameters and medication administered during the 
intervention and postoperatively for 12 hours. We analysed 
all anaesthesia-related complications and anaesthesia-
related side effects that occurred during the intervention 
and entire hospital stay.
results We analysed all 853 TAVI procedures. The mean 
patient age was 79 ± 6 years. In 99.5% of cases, we used 
volatile-based anaesthesia. 2.8% (n=24; transfemoral (TF): 
n=19 [3.8%]; transapical (TA): n=5 [1.4%]) of all cases 
suffered from anaesthesia-related complications. 819 
(TF: n=447; TA: n=372) anaesthesia-related side effects 
occurred in 586 (68.7%, TF: n=325 [64.2%], TA: n=261 
[75.2%]) patients. Neither the complications nor the side 
effects had any serious consequences. Intraoperative 
hypothermia in 44% of cases (TF: n=202 [39.9%]; TA: 
n=173 [49.9%]) and postoperative nausea and vomiting 
in 27% (n=232; TF: n=131 [25.9%], TA: n=101 [29.1%]) 
of cases were the most common anaesthesia-related side 
effects.
Conclusion In this study, serious anaesthesia-related 
complications were rarely seen, and non-critical 
anaesthesia-related side effects could have been avoided 
through consistent prophylaxis and management. 
Therefore, despite their high anaesthetic risk, general 
anaesthesia is justifiable in patients who underwent TAVI.
IntrODuCtIOn 
As life expectancy is increasing worldwide, 
a growing number of elderly multimorbid 
patients will require surgery and anaesthesia 
in the future. In the 16 million interventions 
that took place in Germany in 2013, 42% of 
the patients were older than 65 years.1 The 
number of pre-existing diseases, the Amer-
ican Society of Anesthesiologists (ASA) 
status and therefore the perioperative risk 
increase with older age.2 3 Many interven-
tions are increasingly performed on high-risk 
patients to meet the needs of an older and 
multimorbid patient population. Therefore, 
minimally invasive techniques are increasing. 
One of these minimally invasive proce-
dures is transcatheter aortic valve implan-
tation (TAVI) in patients with aortic valve 
stenosis. TAVI may be performed in patients 
with high and moderate surgical risks by 
dispensing with invasive measures, such as 
sternotomy and cardioplegia.4 Currently, 
TAVI is performed under local anaesthesia 
(LA) or general anaesthesia (GA). GA might 
offer comfortable conditions for interven-
tion, for example, the use of transoesopha-
geal echocardiography (TEE), for a safe and 
optimal valve implantation.5 6 
Anaesthesia-related complications and 
mortality have been significantly reduced 
in the last years.7 Nevertheless, anaesthe-
sia-related side effects, such as postoperative 
nausea and vomiting (PONV) or delirium, 
should not be underestimated. First, patients 
fear anaesthetic side effects.8 9 Second, these 
strengths and limitations of this study
 ► Our study is retrospective and not prospective 
randomised.
 ► Due to the retrospective study design, inconsistent 
documentation cannot be excluded.
 ► We can provide reliable data because of the large 
study size.
 ► Multivariable analysis was used to minimise con-
founding bias.
 ► This manuscript focusses on anaesthesia-related 
complications and side effects in patients who un-
derwent transcatheter aortic valve implantation.
 o
n
 3 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025825 on 1 May 2019. Downloaded from 
2 Goldfuss S, et al. BMJ Open 2019;9:e025825. doi:10.1136/bmjopen-2018-025825
Open access 
side effects are also organisationally and economically 
challenging because they may lead to prolonged hospital 
stays and are associated with high healthcare costs.10–12 
This study examines anaesthesia-related complications 
and side effects in patients undergoing TAVI.
MethODs
In this study, after obtaining the consent of the University 
of Regensburg’s Ethics Commission, all data from each 
TAVI procedure performed at the University Hospital 
Regensburg between January 2009 and July 2015 were 
retrospectively obtained and analysed for anaesthesia-re-
lated complications and anaesthesia-related side effects. 
Some data (eg, procedural time, intervention related 
complications, acute kidney injury) have already been 
presented elsewhere.13
Data
Data were acquired from anaesthetic charts (Medlinq 
V.1.3, Hamburg, Germany), the patient document system 
used in the intensive care unit (ICU) and intermediate 
care unit (IMC) (Metavision, iMDsoft, Tel Aviv, Israel) 
and medical reports from the electronic hospital infor-
mation system (SAP, Walldorf, Germany) from the preop-
erative, intraoperative, and postoperative periods until 
the patients were discharged from the hospital.
Demographic data, such as age, sex, body mass index 
(BMI), ASA, New York Heart Association Functional Clas-
sification, European System for Cardiac Operative Risk 
Evaluation (EuroSCORE), anaesthesia-related parame-
ters, side effects, complications and risk scores, clinical 
characteristics and recent illness, were obtained.14 15 Vital 
sign measurements (ie, heart rate, blood pressure and 
SpO2) at defined times, as well as drugs administered 
throughout the TAVI procedure and in the ICU (first 
12 hours), were acquired.13
We differentiated between side effects and compli-
cations. Anaesthesia-related side effects included: 
hypoxaemia (SpO2 <90%), hypothermia (body tempera-
ture <36°C), hypotension (intraoperatively, Mean Arte-
rial Pressure (MAP) <50 mm Hg; postoperatively, MAP 
<60 mm Hg), delirium and PONV (all patients who 
suffered from PONV or delirium and were treated and/
or had a note in their medical reports).10 16–18 Anaes-
thesia-related complications included cardiac arrest not 
directly associated with the intervention itself, difficult 
airway management and airway damage, laryngospasm, 
allergic reaction and vascular damage.
Procedure
All procedures were performed according to the 
German guidelines for TAVI procedures.19 Prior to GA, 
the patients received oral premedication (ie, dipotas-
sium clorazepate, melperone, zopiclone or midazolam), 
depending on each patient’s risk and the anaesthesiolo-
gist’s preferences.
The intervention was performed in general as follows: 
after being placed on a warming system, each patient 
received two intravenous cannulas, an arterial line in 
the radial artery and a central venous catheter in the 
internal jugular vein or the subclavian vein. Bladder 
catheters, with temperature measurement, were used 
in each patient. The patients received right ventricular 
pacemakers for rapid ventricular pacing during balloon 
aortic valvuloplasty and valve expansion. Preoxygenation 
was performed with pure oxygen using a facemask. In 
general, the anaesthetic induction regimen consisted 
of bolus doses of etomidate, rocuronium bromide and 
a continuous infusion of remifentanil. Anaesthesia was 
maintained with sevoflurane or desflurane. Piritramide 
and metamizole were used as additional pain medication. 
PONV prophylaxis was used intraoperatively, depending 
on the patient’s risk. Cardiovascular drugs (eg, norepi-
nephrine and dobutamine) were administered as needed. 
The responsible cardiac anaesthesiologist decided about 
the medication type and dose. The patients received 
endotracheal intubation. Respiratory gases were sampled 
at the filter and continuously displayed by the ventilator. 
Antibiotic prophylaxis with cefuroxime was applied 
immediately before the procedure. The intraoperative 
monitoring included 5-lead ECG, pulse oximetry, invasive 
blood pressure, central venous pressure, heart rate, respi-
ration parameters, bladder temperature and serial arterial 
blood gas analysis. Intraoperative TEE was performed, if 
possible. Heparin (0.5–1 IU/kg) was administered intra-
operatively. The anticoagulant effect was monitored with 
an activated coagulation time value >250 s. At the end of 
the procedure, heparin was antagonised with protamine 
on a 1:1 basis. The goal was to perform tracheal extuba-
tion in the operating room. In cases of intervention-re-
lated complications or hypothermia <36°C, the time of 
extubation was decided on a case-by-case basis. After the 
intervention, the patients were immediately transferred 
to one of our three ICUs for monitoring. Depending on 
their physical condition, they were taken to the general 
ward or an IMC afterwards.13
Patient and public involvement
Patients were not involved in the study.
Statistics
For the data collection, we used Excel (Excel 2013, 
Microsoft Corporation, Redmond, Washington, USA). 
We analysed the data with SPSS (IBM SPSS Statistics 
V.24.0 for Windows, IBM Corporation). Frequency 
distributions and percentage rates were used for 
the categorical variables. Data are displayed as the 
mean±SD deviation or median with range. We used the 
χ2 test (based on Pearson’s χ2 test), the two-sided t-test 
and univariate and multivariate logistic regression anal-
yses to compare the transapical (TA) group and the 
transfemoral (TF) group. P<0.05 was regarded as statis-
tically significant.
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results
Patients
A total of 853 TF and TA TAVIs were performed during 
the study period. All cases could be analysed retrospec-
tively. TF access was selected in 506 patients (59.3%), 
while TA-TAVI was performed in 347 patients (40.7%). 
In most of the cases, Medtronic Edwards SAPIEN 
(Edwards Lifesciences Corporation, Irvine, California, 
USA) (n=420 [49%]) and Symetis Valves (Boston Scien-
tific Corporation, Marlborough, Massachusetts, USA) 
(n=219 [26%]) were implanted. CoreValve (CoreValve 
Revalving System, Medtronic, Minneapolis, USA) was 
used in 16% of the cases (n=134). In the rest of the cases 
(n=80), the valve type could not be gathered from our 
sources.13
The mean patient age was 79±6 years, and the mean 
BMI was 27±5 kg/m2. In total, 98.8% of the TF group and 
98.2% of TA patients had an ASA status of 3 or higher. 
Demographic data, as well as basic preoperative data, 
previous illnesses and an overview of the current airway 
classifications of the patients are summarised in table 1. 
In three TF patients (0.4%), a ‘difficult airway’ was docu-
mented in the premedication protocol.
All procedures were performed under GA. A total of 
849 (99.5%) procedures took place under volatile-based 
anaesthesia. Total intravenous anaesthesia was used in 
four TA procedures.
Anaesthesia-related complications
Twenty-six anaesthesia-related complications occurred 
in 24 patients of the 853 patients (2.8%). Twenty-one 
complications occurred in TF (n=19; [3.8%]) and five in 
TA (n=5; [1.4%]). Among these complications were six 
(0.7%) difficult intubations, one (0.1%) aspiration, eight 
(0.9%) airway damages, three (0.4%) tooth damages, two 
(0.2%) laryngospasms, three (0.4%) allergic reactions, 
two (0.2%) vascular damages and one (0.1%) cardiopul-
monary resuscitation (CPR) before the start of the inter-
vention (table 2).
This was a TF patient with a EuroSCORE of 19, a pre-ex-
isting pneumonia and recurrent syncope. Following a 
risk assessment, it was nevertheless decided to continue 
the intervention. Pulseless electrical activity was noted 
during induction. Successful CPR of the patient was 
performed. The patient was hypothermic (35.1°C) after 
successful TAVI, so the trachea of the patient could not 
be extubated. He was transferred to the ICU and success-
fully extubated after 68 hours, moved to a normal ward 
after 8 days and was discharged after 17 days. In our view, 
there were several reasons attributable for the cardiac 
arrest.
Anaesthesia-related side effects
Furthermore, 819 anaesthesia-related side effects 
occurred in 586 of all 853 patients (68.7%; TF: n=325 
[64.2%], TA: n=261 [75.2%]). These side effects are 
listed in table 2.
PONV
A total of 232 patients suffered from PONV requiring 
therapy. Female gender (p<0.001), a history of PONV 
(P=0.036) and postoperatively administered opioids 
(p=0.015) were significant risk factors. The PONV rate 
(27.7%) was not significantly elevated (p=0.112) in 
non-smokers (n=819) compared with smokers (n=32; 
[15.2%]). Age, BMI and the duration of the intervention 
also had no statistically significant effect on the PONV 
rate. The average Apfel risk score for PONV was 2.2±0.8 
for all patients. The PONV risk increased by 78.3% for 
each score point (p<0.001). An overview of the patients’ 
Apfel score is shown in table 1.
Overall, 17.5% (n=149) of the patients received PONV 
prophylaxis intraoperatively. A maximum of two agents 
were administered per patient for prophylaxis. Figure 1 
shows the number of agents administered, depending on 
the Apfel risk score for PONV.
The incidence of PONV in patients with at least two 
PONV risk factors was reduced from 31.5% to 25.8% 
(p=0.24) through prophylaxis. Figure 2 shows the inci-
dence of PONV depending on the Apfel score with and 
without intraoperative PONV prophylaxis.
Delirium
Of the 74 patients with delirium, 30 (40.5%) belonged 
to the TF group, while 44 (59.5%) belonged to the TA 
group (p=0.001). The multivariate analysis showed that 
male gender (p=0.038), transapical access (p=0.001) and 
pre-existing dementia (p=0.047) influenced the delirium 
rate significantly and independently. Neither the lack of 
extubation in the surgical room (10.2% vs 8.5%, p=0.573) 
nor intervention-related intraoperative complications 
influenced the incidence of delirium (p=0.413). Multivar-
iate regression analysis showed that delirium had a signif-
icant influence on length of stay (LOS) at ICU (p=0.012), 
IMC (p<0.001) and in hospital (p=0.033; figure 3).
Hypothermia
The body temperature at extubation was available for 781 
patients. Three hundred and seventy-five of them (44.0%) 
were hypothermic by 0.8±1.1 degrees on average. A total 
of 264 patients had a body temperature >35° C, and 47 
patients had a body temperature <35°C.
The risk of hypothermia in the surgical room decreased 
with increasing weight (4.3% per kg/m2; p=0.05). 
TA access (p=0.025), BMI category (p=0.016) and age 
older than 80 years (p=0.031) were independent and 
significant risk factors for the occurrence of hypothermia 
in the multivariate analysis. Intervention-related compli-
cations were no risk factors.
Intervention in the hypothermic group lasted 
1:29±0:44 hours and was 5 min longer on average. This 
difference was not statistically significant (p=0.151). 
The induction in both groups was of the same duration, 
lasting an average of 0:38±0:11 hours.
Neither the postoperative complication rate (p=0.956) 
nor the mortality rate (p=0.314) was significantly 
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Table 1 Patient demographics and anaesthesia-related variables
All TF
TA (n=347) P value(n=853) (n=506)
Age 79±6 79±6 79±6 0.238
Female sex 448 (52.5) 278 (54.9) 170 (49.0) 0.088
BMI (kg/m2) 27±5 27±5 27±5 0.535
EuroSCORE 19.0±13.7 17.7±12.2 20.8±15.4 0.002
Codiseases 
  AHT 677 (79.4) 393 (77.7) 284 (81.8) 0.133
  PHT 450 (52.8) 267 (52.8) 183 (52.7) 0.993
  CAD 523 (61.3) 306 (60.5) 217 (62.5) 0.543
  Diabetes 305 (35.8) 173 (34.2) 132 (38.0) 0.252
  Stroke/TIA 138 (16.2) 81 (16) 57 (16.4) 0.871
  Dementia 18 (2.1) 13 (2.6) 5 (1.4) 0.236
  ICA-stenosis 74 (8.7) 36 (7.1) 38 (11.0) 0.059
  COPD 114 (13.4) 65 (12.8) 49 (14.1) 0.114
  Restrictive ventilation disorder 123 (14.4) 64 (12.6) 59 (17.0) 0.082
  GORD 76 (8.9) 45 (8.9) 31 (8.9) 0.984
ASA 
  Mean 3.3±0.5 3.3±0.5 3.4±0.5 0.048
  1 0 0 0
  2 7 (0.8) 3 (0.6) 4 (1.2)
  3 574 (67.3) 357 (70.6) 217 (62.5)
  4 264 (30.9) 141 (27.9) 123 (35.4)
  5 3 (0.4) 2 (0.4) 1 (0.3)
  Not specified 5 (0.6) 3 (0.6) 2 (0.6)
MP 
  Mean 1.8±0.7 1.8±0.7 1.8±0.7 0.387
  1 200 (23.4) 115 (22.7) 85 (24.5)
  2 285 (33.4) 171 (33.8) 114 (32.9)
  3 65 (7.6) 40 (7.9) 25 (7.2)
  4 7 (0.8) 5 (1.0) 2 (0.6)
  Not specified 296 (34.7) 175 (34.6) 121 (34.9)
CL 
  Mean 1.1±0.3 1.1±0.4 1.1±0.3 0.505
  1 758 (88.9) 449 (88.7) 309 (89.0)
  2 44 (5.2) 28 (5.5) 16 (4.6)
  3 14 (1.6) 9 (1.8) 5 (1.4)
  4 0 0 0
  Not specified 37 (4.3) 20 (4.0) 17 (4.9)
PONV risk* 
  Mean 2.2±0.8 2.0±0.8 2.5±0.7 <0.001
  0 8 (0.9) 7 (1.4) 1 (0.3)
  1 160 (18.8) 140 (27.7) 20 (5.8)
  2 403 (47.2) 240 (47.4) 163 (47.0)
  3 250 (29.3) 101 (20.0) 149 (42.9)
  4 32 (3.8) 18 (3.6) 14 (4.0)
*Score from Apfel; AHT, arterial hypertension; all data are presented as n (number) and (%) or as the mean ±SD.
ASA, American Society of Anaesthesiologists Classification; BMI, body mass index; CAD, coronary artery disease; CL, Cormack-Lehane Score; 
COPD, chronic obstructive pulmonary disease; EuroSCORE, European System for Cardiac Operative Risk Evaluation; GORD, gastro-oesophageal 
reflux disease; ICA-stenosis, relevant stenosis of the internal carotid artery; MP, Mallampati Score; PHT, pulmonary hypertension, PONV, postoperative 
nausea and vomiting; TA, transapical; TF, transfemoral; TIA, transient ischaemic attack.
 o
n
 3 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025825 on 1 May 2019. Downloaded from 
5Goldfuss S, et al. BMJ Open 2019;9:e025825. doi:10.1136/bmjopen-2018-025825
Open access
Table 2 Anaesthesia-related complications and side effects
All: n=853 TF: n=506 TA: n=347 P value
Complications 26* 21* 5*
Preoperative CPR 1 (0.1) 1 (0.2) 0 (0) 0.407
Difficult intubation 6 (0.7) 6 (1.2) 0 (0) 0.014
Tracheal tube 
misplacement
0 (0) 0 (0) 0 (0)
Aspiration 1 (0.1) 0 (0) 1 (0.3) 0.318
Airway damage 8 (0.9) 6 (1.2) 2 (0.6) 0.334
Tooth damage 3 (0.4) 1 (0.2) 2 (0.6) 0.403
Laryngospasm 2 (0.2) 2 (0.4) 0 (0) 0.158
Allergic reaction 3 (0.4) 3 (0.6) 0 (0) 0.083
Vascular damage 2 (0.2) 2 (0.4) 0 (0) 0.158
Side effects 819* 447* 372*
Preoperative
Hypoxaemia† 75 (8.8) 48 (9.5) 27 (7.8) 0.38
Intraoperative 436* 238* 198*
Hypothermia 375 (44.0) 202 (39.9) 173 (49.9) 0.004
Hypotension 61 (7.1) 36 (7.1) 25 (7.2) 0.96
Postoperative 308* 161* 147*
PONV 232 (27.2) 131 (25.9) 101 (29.1) 0.304
Delirium 74 (8.7) 30 (5.9) 44 (12.7) 0.001
Narcotic hangover 2 (0.2) 0 (0) 2 (0.6) 0.158
All data are presented as n (number) and  (%)  (=patients  with complications or side effects related to the total number of  patients  in this 
subgroup). 
*Total number of complications and side effects; some patients suffered from more than one complication or side effect.
†Before the start of anaesthesia.
CPR, cardiopulmonary resuscitation; PONV, postoperative nausea and vomiting; TF, transfemoral; TA, transapical. 
Figure 1 Number of prophylactically administered 
postoperative nausea and vomiting (PONV) medications, 
depending on the patients’ PONV risk. All data are presented 
as n (number).
Figure 2 Incidence of postoperative nausea and vomiting 
(PONV), depending on the patient’s PONV risk: intraoperative 
prophylaxis versus no prophylaxis. 1: p=0.746; 2: p=0.34; 3: 
p=0.213; 4: p=0.055. All data are presented in per cent.
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increased in the patients with hypothermia compared 
with the patients with normothermia.
Delayed postoperative extubation
A total of 100 patients were not extubated in the operating 
room ([11.7%]; TF: n=51 [10.1%], TA: n=49 [14.1%], 
figure 3). Fifty-nine of the patients were not extubated 
due to intervention-related complications (eg, bleeding, 
intraoperative stroke and myocardial infarction, intraop-
erative CPR). Hypothermia (≤35°C, n=11; >35°C, n=11) 
was the second most common cause (n=22) (figure 4). In 
addition, 10 patients were not extubated due to pre-ex-
isting conditions (chronic obstructive pulmonary disease 
[COPD] and pre-existing pneumonia) and nine patients 
were not extubated due to interventional causes (prophy-
lactic extracorporeal membrane oxygenation (ECMO) 
protection, concomitant operative coronary artery bypass 
grafting) (figure 4).
A total of 92% (TF: n=45 [88.2%], TA: n=47 [95.9%]) 
of the 100 non-extubated patients were extubated during 
their hospital stay. Sixty-five (70.7%)) of these 92 patients 
were extubated postoperatively within the first 24 hours. 
All 22 patients, who were not extubated only because of 
hypothermia, could be extubated within 27 hours.
The pneumonia rate in the non-extubated patients was 
significantly higher (15.0% vs 6.2%, p=0.002). Ten of the 
15 patients (66.7%), who developed pneumonia postop-
eratively, were not extubated due to complications. Two 
(13.3%) of the patients who developed pneumonia were 
not extubated due to hypothermia.
Sixteen (17.4%) of the 92 patients, who were extu-
bated with delay, died during their hospital stay. In all, 24 
(24.0%) of those patients who were not extubated in the 
operating theatre died. None of these deceased patients 
was not extubated due to hypothermia.
Hypoxaemia
Pulsoxymetric oxygen saturation was observed in 732 
patients before the start of anaesthesia, and 75 of 
these patients (10.5%) were hypoxaemic. Fifty-three of 
these patients (70.7%) suffered from mild hypoxaemia 
(SpO2 85–90), while 22 patients (29.3%, TF: n=6, TA: 
n=16) had severe hypoxaemia (SpO2 ≤85). Of the 75 
patients with hypoxaemia, 46 patients (61.3%, p=0.065) 
received midazolam as premedication. Midazolam as 
premedication was given in 375 cases.
BMI (28.6±5.6 vs 26.5±4.7; p=0.001), the logistic Euro-
SCORE (16.3±1.9 vs 13.2±0.5; p=0024), pre-existing 
pulmonary restriction (p=0.0002) and pulmonary hyper-
tension (p=0.037) were independent significant risk 
factors for hypoxaemia in the multivariate regression 
analysis. In addition, the amount of midazolam used as 
premedication correlated with the hypoxaemia rate. The 
hypoxaemia rate increases by 12.7% for each milligram 
of administered midazolam (p=0.028). However, this did 
not prove to be an independent, significant risk factor for 
hypoxaemia (p=0.076).
Pre-existing COPD or an obstruction detected on 
spirometry also demonstrated no significant effect on the 
hypoxaemia rate (p=0.534, p=0.389).
A higher mortality rate (12.0% vs 5.5%) was noted 
among the patients who were hypoxaemic during the 
induction phase. But in multivariate regression analysis, 
hypoxaemia did not have any significant effect on the 
mortality rate (p=0.108), nor the duration of stay in the 
ICU (p=0.537) nor the postoperative complication rate 
(p=0.209).
DIsCussIOn
Overall, serious anaesthesia-related complications 
were rare. The complications mainly included mild 
respiratory lesions and difficult intubation. Side 
effects occurred in approximately 70% of the patients. 
However, most of these effects did not have any serious 
consequences and potentially could have been avoided 
in most patients. Furthermore, many of these side 
effects might be multifactorial. The most common 
side effects were intraoperative hypothermia in 375 
cases and PONV in 232 cases. TA access and low BMI 
proved to be risk factors for hypothermia. The primary 
risk factors for the occurrence of PONV were female 
Figure 3 Length of stay (LOS) in the intensive care unit 
(ICU), intermediate care unit (IMC) and hospital for patients 
with delirium versus patients without delirium. ICU: p=0.054; 
IMC: p=0.002; hospital: p=0.035. All data are presented as 
mean ±SD.
Figure 4 Causes for non-extubation in the surgical room. All 
data are presented in per cent.
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gender, postoperatively administered opioids and a 
history of PONV.
Schiff et al have reported that the rate of severe anaes-
thesia-related complications is 26.2 per million anaes-
thesia cases.7 However, Schwilk et al have reported a 
complication rate of 35% among 23 000 anaesthetised 
patients.20 Overall, the rate of anaesthesia-related 
complications in our study was almost 3%. Comparing 
these heterogeneous complication rates proved to be 
difficult because the methodologies and assessments of 
the complications differed among the studies. In addi-
tion, these studies involved different interventions and 
different patient populations. The perioperative risk 
increases significantly with increasing ASA status and 
age.2 3 In the present study, the patients had an average 
ASA status of 3.3±0.5, whereas in the study of Schwilk 
et al, more than half of the patients had an ASA status 
of 1 or 2; Schiff et al exclusively studied anaesthesia in 
patients with an ASA status of 1 or 2.7 20 In addition, 
Schiff et al excluded milder anaesthesia-related compli-
cations, such as tooth damage, and so on, from their 
investigations.7 In contrast, the present study provides 
an overview of all described complications.
The incidence of delirium is reported between 8% 
and 54% in elderly patients and 21% following invasive 
cardiac surgery.21 22 The incidence of delirium after TAVI 
is reported as 29% in the literature.23 The incidence of 
delirium in our study was 8.7%. The reported incidences 
of delirium vary greatly, depending on the study design. 
Retrospective analyses of patient data are associated 
with the lowest incidences of delirium.11 The far more 
frequently observed type of hypoactive delirium is easily 
overlooked in clinical practice and is not documented.11 24 
Therefore, approximately two-thirds of all delirium cases 
are not recognised.24 Maniar et al have also documented 
that hypoactive delirium is the most frequent type of 
delirium in patients who underwent TAVI. Delirium 
occurs significantly more frequently following TA then 
TF procedures.23 This difference was also confirmed in 
the present study. This can probably be explained by the 
overall worse pre-existing conditions of TA patients. They 
had a significantly higher EuroSCORE and ASA status in 
our study. Furthermore, the invasiveness of the proce-
dure itself and postoperative pain might be risk factors.23 
Maniar et al showed that the incidence of postoperative 
delirium in surgical aortic valve replacement or TAVI is 
almost comparable (33% vs 29%; p=0.4).23
Overall, more than 95 risk factors are listed in the litera-
ture, with marked heterogeneity.21 The following primary 
risk factors for the occurrence of delirium after cardiac 
surgery have been described: cognitive impairment, such 
as pre-existing dementia, hypoalbuminaemia, depression 
and post-TIA or stroke status.11 22 Pre-existing dementia 
was also found to be a statistically significant risk factor for 
the occurrence of delirium in the present study. Further-
more, delirium leads to prolonged ICU and hospital stays 
and is therefore associated with high costs.11 21 23 These 
findings were also observed in our study.
The postoperative mortality and morbidity rates are also 
higher in patients with delirium, according to the liter-
ature.11 23 24 The incidence of pneumonia is particularly 
high in patients with delirium.24 Patients with delirium also 
demonstrated a significantly higher incidence of pneumonia 
in the present study. This increase in the incidence of pneu-
monia is likely due to the longer hospital stay, as delirium was 
not a significant independent risk factor in the multivariate 
analysis. Although the mortality rate and number of compli-
cations were increased in the present study, these differences 
were not statistically significant.
Depending on the risk constellation, PONV occurs in 
up to 60% of cases.25 A PONV incidence of 35% has been 
described following TAVI.26 A PONV incidence of 28% was 
observed in the present study. Of the generally known PONV 
risk factors, female gender and a history of PONV were iden-
tified as significant risk factors in the present study.15 The 
PONV rate was also higher in non-smokers; however, this 
finding was not statistically significant, primarily due to the 
unequal distribution or documentation of smokers (n=33) 
and non-smokers (n=820) in the present study.
Furthermore, anaesthesia-related PONV risk factors 
have been described, particularly the duration of anaes-
thesia and the intraoperative and postoperative admin-
istration of opioids, in addition to the use of inhalational 
anaesthetic agents and nitrous oxide.12 The postopera-
tive administration of opioids also resulted in a signif-
icant increase in the PONV rate in our study, while 
no relationship was observed between the duration of 
anaesthesia and the PONV rate. PONV prophylaxis is 
rarely administered, although the principal risk factors 
for its occurrence are known, and PONV itself is asso-
ciated with several complications.25 27 Frenzel et al have 
described a 36% compliance for two existing PONV risk 
factors and 22% for three existing risk factors during 
the implementation of appropriate prophylaxis.27 
PONV prophylaxis was also rarely administered in this 
study. Only 19% of patients with an Apfel score ≥2 
received appropriate PONV prophylaxis, which may be 
due to our patient population. On one hand, the PONV 
risk decreases with increasing age.25 Therefore, this 
rate was possibly underestimated. On the other hand, 
prophylactically administered 5-HT3 antagonists and 
droperidol significantly reduce the incidence of PONV 
but also lead to prolonged QT intervals, increasing the 
risk of torsade-de-pointes tachycardia.12 28 Patients with 
cardiac disease, as in the present study, are exposed to 
this risk, which may be the cause of reduced compli-
ance, although no alternatives were administered.28
In the present study, 8.7% of patients suffered from 
hypoxaemia before induction, which was mild in 6.2% 
of patients and severe in 2.6%. Preoperative premedica-
tion is always associated with the occurrence of hypox-
aemia.29 30 Royse et al have reported that the incidence 
of hypoxaemia was 30% after premedication.29 The fact 
that our incidence is significantly lower could be because 
Royse et al used a benzodiazepine–opiate combination, 
which also enhances respiratory depression.30 31 However, 
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midazolam alone, used as standard medication because 
of its low propensity for side effects, also causes respira-
tory depression.30 31 Respiratory minute volume drops 
drastically after midazolam, particularly in patients older 
than 65 years of age.31 In our study, the hypoxaemia rate 
increased with the amount of midazolam administered 
as premedication. Therefore, we stopped giving midaz-
olam to patients who underwent TAVI at our hospital. 
Royse et al have shown that additional oxygen adminis-
tration after premedication can significantly reduce the 
incidence of hypoxaemia. They recommend monitoring 
and oxygen administration immediately after premedi-
cation in patients at risk of hypoxaemia.29 However, this 
approach is complex and expensive. In addition, benzo-
diazepines have a delirogenic potential, which is why 
premedication in patients undergoing TAVI should be 
completely eliminated in the future.32
There are recent studies comparing LA and GA for 
TAVI. They show that both ways are comparable in 
procedure-related outcomes.6 33–35 LA in TAVI has the 
advantages of a shorter induction time, more stable 
haemodynamic conditions, a faster postoperative mobili-
sation and a shorter LOS.34 35 GA provides a better patient 
comfort with more stable surgical conditions. In addition, 
periprocedural complications can be better controlled. 
Furthermore, continuous TEE monitoring is possible 
under GA and thus patients have a reduced incidence of 
aortic regurgitation.6 34 35 Anaesthesia-related complica-
tions and side effects have not been considered in these 
studies. Our study shows that anaesthesia-related compli-
cations are relatively rare, and side effects can be avoided 
by adequate prophylaxis.
limitations
The percentage of TF patients in the collective perma-
nently rose up to 74.4% during the study period. 
Furthermore, better operative techniques could reduce 
complication rates and improve patient outcome. Addi-
tionally, other reasons (eg, emergency TAVI, diagnostic 
related groups (DRG) system, different standard oper-
ating procedures on the ICU) might have influenced 
ICU, IMC and hospital stay.13 Complications and side 
effects seen in this study might not be totally attribut-
able to anaesthesia. For example, delirium arises from 
different predisposing and precipitating factors.22 There-
fore, a prospective study might be more sensitive to divide 
complications and side effects to the main cause.
COnClusIOn
This study demonstrated a low rate of anaesthesia-related 
complications. Anaesthesia-related side effects could 
have been avoided in most of the cases through good 
prophylaxis. In our opinion, patients who underwent 
TAVI can decently be managed under GA, and this might 
offer advantages in the management (eg, use of TEE). 
However, they need a comprehensive regime throughout 
their hospitalisation stay. Therefore, due to the results of 
this study, the organisation of patients who underwent 
TAVI has been changed in Regensburg: for example, 
premedication with benzodiazepine is no longer in use 
and prewarming has been recognised as an important 
standard by all colleagues.
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